Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CTMX vs CRMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRMD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–3 Matrix Metrics)

CRMD Overall Winner 6-Pillar Tally: CTMX 1 – 5 CRMD Matrix Metrics: CTMX 3 – 6 CRMD

As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over CytomX Therapeutics, Inc. (CTMX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CTMX carries a Unified Composite Score of 53.1/100 (HOLD) at $1.96 (14.2x Forward P/E, -676.4% operating margin), whereas CRMD carries 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin).

  • Technical & Structure Timing Caution: CTMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.1); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CTMX vs CRMD
CTMX NASDAQ
CytomX Therapeutics, Inc.
Pharmaceutical Preparations
$1.96
-4.17% 1D
Market Cap $436.0M
TTM Revenue $14M
Forward P/E 14.2x
Beta / 30D Vol 1.48β · 78% Vol
Unified Composite Score
53.1 / 100 HOLD
Tech 66.0 Fund 64.0 Flow 69.0 Mom 49.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.1%), weak momentum, RSI 39
RSI-14: 39.1 · SMA20: $2.22 · SMA50: $2.53
CRMD NASDAQ Head-to-Head Winner
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap $384.7M
TTM Revenue $1.05B
Forward P/E 49.0x
Beta / 30D Vol 1.20β · 107% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 60.0 Fund 60.0 Flow 69.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.2%), weak momentum, RSI 29
RSI-14: 29.3 · SMA20: $6.32 · SMA50: $7.11

6-Pillar Scorecard Institutional Category Breakdown (CTMX 1 – 5 CRMD)

Columns: Metric · CTMX · CRMD
1. Valuation Multiples CTMX
Forward P/E 14.2x 49.0x
Trailing P/E 14.2x 2.4x
PEG Ratio N/M 3.79x
EV / Revenue 29.0x N/M
2. Growth & Scale CRMD
Revenue Growth (YoY) -71.7% -47.7%
Earnings Growth (YoY) +60.6% +6.7%
TTM Revenue (USD) $14M $1.05B
Market Cap $436.0M $384.7M
3. Profitability & Quality CRMD
Gross Margin 100.0% 87.4%
Operating Margin -676.4% 41.0%
Net Profit Margin 0.0% 15.5%
Return on Equity (ROE) -43.5% 15.3%
4. Balance Sheet & Cash Flow CRMD
Cash Generation (TTM) -$51M $785M
Cash Flow Margin N/A 74.6%
Net Cash / Leverage $30M Net Cash $535M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRMD
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 137.3% (60th %ile) 56.3% (25th %ile)
Put/Call OI Skew N/A 0.69x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat CRMD
OpEx & R&D Intensity N/A 46.4% of Rev ($488M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CTMX (3) vs CRMD (6)
Institutional Metric CTMX CRMD Criterion Row Edge
Market Capitalization
Scale
$436.0M $384.7M Larger Scale CTMX
Trailing P/E Ratio
Valuation
14.2x 2.4x Lower Multiple CRMD
Forward P/E Ratio
Valuation
14.2x 49.0x Lower Multiple CTMX
Revenue Growth (YoY)
Growth
-71.7% -47.7% Higher Growth CRMD
Operating Margin (TTM)
Profitability
-676.4% 41.0% Higher Margin CRMD
Net Profit Margin
Profitability
0.0% 15.5% Higher Margin CRMD
Return on Equity (ROE)
Capital Efficiency
-43.5% 15.3% Higher ROE CRMD
52-Week Range Position
Momentum
1% ($2–$8) 3% ($5–$13) Stronger Trend CRMD
Beta / 30D Volatility
Risk Regime
1.48β · 78% Vol 1.20β · 107% Vol Lower Realized Risk CTMX
Unified Institutional Score
Composite Signal
53.1 / 100 (HOLD) 53.2 / 100 (HOLD) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$14M $1.05B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 87.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.0x EV/Rev 3.79x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$51M ($30M Net Cash) $785M ($535M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CTMX +18.05 pp
CTMX: -14.25% · CRMD: -32.3%
3M Horizon CRMD +2.49 pp
CTMX: -42.33% · CRMD: -39.84%
6M Horizon CRMD +6.28 pp
CTMX: -44.14% · CRMD: -37.86%
1Y Horizon CTMX +6.81 pp
CTMX: -49.35% · CRMD: -56.16%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CTMX Revenue CRMD Revenue CTMX Op. Margin CRMD Op. Margin Margin Leader
FY2018 $60M $0M -130.9% -6250.4% CTMX
FY2019 $30M $0M -525.9% -7416.3% CTMX
FY2020 $70M $0M -117.7% -11378.4% CTMX
FY2021 $40M $0M -311.0% -15417.5% CTMX
FY2022 $50M $0M -190.6% -46819.9% CTMX
FY2023 $100M N/A -6.4% N/A CTMX
FY2024 $140M $40M 18.1% -51.4% CTMX
FY2025 $80M $310M -29.3% 48.2% CRMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CTMX BREAKDOWN
170d in phase · OBV DISTRIBUTION
Current IV 137.3%
IV Percentile 60th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CTMX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRMD BREAKDOWN
109d in phase · OBV DISTRIBUTION
Current IV 56.3%
IV Percentile 25th %ile
Put/Call OI Skew 0.69x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CTMX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $436.0M market capitalization and -676.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CRMD Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $384.7M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment 46.4% of Rev ($488M)
90D Engineering Disclosures 0 Published

Investor FAQ CTMX vs CRMD Key Questions & Quantitative Answers

As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over CytomX Therapeutics, Inc. (CTMX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CTMX carries a Unified Composite Score of 53.1/100 (HOLD) at $1.96 (14.2x Forward P/E, -676.4% operating margin), whereas CRMD carries 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin). Technical & Structure Timing Caution: CTMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.1); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRMD leads the Growth & Scale pillar: CTMX posts -71.7% YoY revenue growth and +60.6% YoY earnings growth on $14M TTM revenue (100.0% gross margin, -676.4% operating margin), compared with CRMD at -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CTMX cumulative revenue shifted +33.3% while CRMD shifted +675.0%. In operating R&D and SG&A reinvestment, CTMX deploys N/A (0 90-day corporate R&D disclosures) versus 46.4% of Rev ($488M) (0 disclosures) for CRMD.

CTMX screens cheaper on headline valuation multiples. CTMX trades at 14.2x Forward P/E, 14.2x Trailing P/E, N/M PEG, and 29.0x EV/Revenue (unreported FCF margin), whereas CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CTMX (-43.5% ROE) versus CRMD (15.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CTMX carries 137.3% implied volatility (60th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.48β · 78% Vol realized risk). By comparison, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.